The Management of Hepatitis B in Liver Transplant Recipients

Sammy Saab; Ping-Yu Chen; Clara E Saab; Myron J Tong

doi:10.1016/j.cld.2016.06.004

The Management of Hepatitis B in Liver Transplant Recipients

Clin Liver Dis. 2016 Nov;20(4):721-736. doi: 10.1016/j.cld.2016.06.004. Epub 2016 Aug 9.

Authors

Sammy Saab¹, Ping-Yu Chen², Clara E Saab³, Myron J Tong⁴

Affiliations

¹ Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA; Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA. Electronic address: SSaab@mednet.ucla.edu.
² Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
³ Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
⁴ Department of Surgery, University of California at Los Angeles, Los Angeles, CA, USA; Huntington Medical Research Institutes, Pasadena, CA, USA.

PMID: 27742010
DOI: 10.1016/j.cld.2016.06.004

Abstract

Liver transplant (LT) is now an established indication for patients with chronic hepatitis B, mainly because of the development and use of hepatitis B immunoglobulin (HBIG) and oral antivirals for prophylaxis. The combination of low-dose HBIG and antivirals has been considered the standard prophylaxis regimen to prevent post-LT recurrence of hepatitis B. The important remaining issues are related to the long-term cost of HBIG and the risk of escape hepatitis B virus (HBV) mutants. Strategies for prevention of HBV after LT are constantly improving. With the availability of new nucleoside/nucleotide analogues, new post-LT strategies also should emerge.

Keywords: Antiviral therapy; Cirrhosis; Hepatitis B; Liver transplant.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use*
Disease Management*
Global Health
Hepatitis B virus*
Hepatitis B* / drug therapy
Hepatitis B* / epidemiology
Hepatitis B* / virology
Humans
Incidence
Liver Transplantation*
Transplant Recipients*

Substances

Antiviral Agents